Cornerstone Pharmaceuticals Initiates Phase 1 Clinical Trial of CPI-613 for the Treatment of Metastatic Colorectal Cancer

Trial sponsored by prominent National Cancer Institute-designated Comprehensive Cancer Center

CRANBURY, NEW JERSEY (January 12, 2015) - Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the field of  cancer metabolism-based therapeutics, today announced the initiation of a Phase 1 clinical trial of CPI-613 Read More >>

 

slider bt care differently

slider bt discovery

500 characters left
nysehome
videohome
videobutton

Know the Science behind

AEMD Platform
Read More >>
Slide item 1

Another Breakthrough
A phase I Study of the Mitochondrial Metabolism Inhibitor CPI-613 in Combination with High Dose Ara-C and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia

Read More >>
Slide item 2

People behind the Success

Our Team
Read More >>
Slide item 3
announcement1
announcement2
announcement3